Q-omics provides the consensus-scored CLEC4O profile across patient tissues and cancer cell-line models. CLEC4O expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CLEC4O is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, CLEC4O RNA expression shows 9,725 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUSC, and TGCT as cancer lineages where CLEC4O shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC4O — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC4O survival associations across molecular data types. CLEC4O RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC4O RNA expression–survival associations across cancer types. High CLEC4O expression shows unfavorable associations in ACC, UCEC and KIRC, but favorable associations in LAML, CHOL and SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CLEC4O RNA expression.
This table summarizes CLEC4O tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC4O. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC4O shows lower tumor expression in LUSC, UCEC, READ, BRCA and COAD and higher tumor expression in HNSC. The LUSC box plot shows higher CLEC4O RNA expression in normal versus tumor tissue (log2 FC = −1.175, t-test p < 0.001).
This table shows molecular features associated with CLEC4O in patient tissues and cancer cell lines. In patient samples, CLEC4O shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
